Products for Out-Licensing

Products Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at BD@nalpharma.com to know more about NAL’s products and partnering opportunities.

Pain Management
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL1279 Lidocaine 4% Patch (LIDO KING™)
OTC via ANDA
NAL1282 Lidocaine 5% 12-Hour Patch
ANDA
NAL1606 Rizatriptan ODF for Migraine
505(b)(2) NDA
NAL1207 Indomethacin 12-Hour Patch
505(b)(2) NDA
NAL1218 Diclofenac Epolamine 12-Hour Patch
ANDA
NAL1219 Diclofenac Na 24-Hour Patch
505(b)(2) NDA
NAL1242 Glycol Salicylate 12-Hour Patch
OTC
NAL1243 Methyl Salicylate Patch
OTC via ANDA
NAL1244 Capsaicin Derivative 12-Hour Patch
OTC
Top